Alzheimer disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• TDP-43 2
• BDNF 0
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

EU-13 is a filter, not a ranking: it only narrows the list.

9 of 9+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Alzheon Inc.· Updated 25 Jun 2026

  “Sponsor business decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

  NCT04187547· Cerecin· Updated 14 Apr 2023

  “Study replaced with a new study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

  NCT07864623· Eisai Inc.· Source

• Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

  NCT07146412· HudsonAlpha Institute for Biotechnology· Source

• A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)

  NCT06682767· Cedars-Sinai Medical Center· Source

• ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness

  NCT07679906· Firalis SA· Source

• Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype

  NCT03876314· University of North Carolina, Greensboro· Source

• ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

  NCT07392723· Michal Schnaider Beeri, Ph.D.· Source

• Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results

  NCT06459583· Banner Health· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 175
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 228
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 672
• Magnetic Resonance Imaging 992
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 533
• Genome-Wide Association Study 215

• Attentive interpretable tabular learning (TabNet) for miRNA expression classification in cervical cancer and Alzheimer's disease.

  BMC Bioinformatics, Oct 2026

• A Lightweight EEG-Based Alzheimer's Disease Detection Framework on an Edge-Computing Platform Toward Future Intelligent Digital Twin Systems.

  J Integr Neurosci, Oct 2026

• Multi-Dimensional Feature Adaptive Gating Network for Multi-View and Whole-Brain Magnetic Resonance Imaging-Based Alzheimer's Disease Classification.

  J Vis Exp, Oct 2026

• Advances in artificial intelligence-driven MRI research in Alzheimer's disease.

  Front Neurol, Oct 2026

• The application progress of artificial intelligence in the diagnosis of Alzheimer's disease.

  Front Neurol, Oct 2026

• Deep learning-based prediction of regional brain Tau PET burden from MRI.

  Alzheimers Dement, Oct 2026

• Neuroimaging Biomarkers for Brain Disorder Diagnosis Using Advanced Learning Techniques.

  Int J Neural Syst, Sept 2026

• Learning age-conditioned brain atlases via free-prototype modeling for brain age prediction.

  Artif Intell Med, Sept 2026

• Predicting conversion from mild cognitive impairment to Alzheimer's disease: A systematic review of deep learning models for early-stage disease classification.

  Ageing Res Rev, Sept 2026

• SynthPET: A 3D generative AI approach for FDG-PET image synthesis from T1-weighted MRI and ASL CBF in Alzheimer's disease.

  Alzheimers Dement, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.